Dec 6 (Reuters) - Drugmaker Nabi Biopharmaceuticals (NABI.O) said it plans to explore alternatives, including sale of the company.
The alternatives may include licensing or development arrangements, joint ventures or strategic alliances and additional share repurchase programs, it said in a statement.
The company also said its board approved the buyback of 65 million common shares. (Reporting by Anant Vijay Kala in Bangalore; Editing by Amitha Rajan)
Experts say there is no single answer to solving global warming, but a handful of technologies could be promising. Check out some of the candidates and join the debate. Full Article
The House of Representatives approved the biggest changes in financial regulation since the Great Depression, marking a win for the Obama administration and congressional Democrats. Full Article
Fear of the market abyss has faded for investors, but another fear is lurking on the horizon, if not already here. Full Article
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
